Lv11
68 积分 2025-08-09 加入
Orelabrutinib, a Selective Bruton's Tyrosine Kinase (BTK) Inhibitor in the Treatment of Primary Immune Thrombocytopenia (ITP)
14天前
已完结
Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia
14天前
已完结
Orelabrutinib: First Approval
14天前
已完结
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance
1个月前
已完结
Orelabrutinib: First Approval
1个月前
已完结
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance
1个月前
已完结
皖公网安备34019202002308
